Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial
A phase II clinical trial suggests the oral medication NA-931 may facilitate significant weight loss while potentially preserving lean muscle mass. The drug targets four distinct receptors, distinguishing it from current GLP-1 based weight management therapies.
🔬ResearchPhoto: medpagetoday.com
Key points
- NA-931 targets four receptors: GLP-1, GIP, glucagon, and IGF-1.
- Participants at the 150 mg dose lost nearly 14% of their body weight in 13 weeks.
- The medication showed lower rates of nausea and vomiting compared to current market-leading weight loss drugs.
A new investigational oral drug, NA-931, demonstrated substantial weight reduction in a randomized phase II clinical trial involving 125 adults with obesity or weight-related comorbidities. Presented at the ObesityWeek annual meeting, the study found that participants taking the highest dose of 150 mg experienced a 13.8% reduction in body weight over 13 weeks, compared to a 1.9% reduction in the placebo group.
The study, led by researchers at Biomed Industries, highlighted that lean mass decreased by only 1.7% during the trial period. This finding is notable when compared to existing GLP-1 and dual-agonist therapies, which have historically been associated with higher proportions of lean mass loss relative to total weight reduction. Researchers noted that preserving muscle mass is particularly important for long-term metabolic health, especially as individuals age.
What to know: The trial utilized DEXA scans to estimate lean soft tissue changes, though these measurements do not directly confirm muscle function. The drug, which targets IGF-1, GLP-1, GIP, and glucagon receptors, also showed a favorable safety profile with gastrointestinal side effects occurring at rates only slightly higher than those observed in the placebo group. As this is a phase II study with a relatively small sample size, further large-scale phase III trials are required to confirm efficacy and long-term safety. Always consult with a healthcare provider before considering new medical treatments for weight management.
Source medpagetoday.com — medpagetoday.com/meetingcoverage/obesityweek/123955 ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…